The Company has sufficient cash at hand to fund operations into August, however the Company will need to raise additional capital to fund its clinical trials and other operating activities, and repay indebtedness in due course. Shareholders should be aware that if the Company's capital raising efforts are unsuccessful, this will have a material adverse effect on the Company's financial position and operations.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines and therapeutic antibodies. The Company is in a large Phase II clinical trial in GBM, with 13 clinical sites across the U.S. The Company has also received clearance from the FDA for a large Phase III trial in prostate cancer, and for Phase I trials in five other cancers. The Company has started, and is currently enrolling patients in, a Phase I/II trial with DCVax(R) for recurrent metastatic ovarian cancer. The Company's second technology platform, involving antibodies to CXCR4, is at the late pre-clinical development stage.
For further information about clinical sites and Company information please visit the company web site at www.nwbio.com.
Statements made in this news release that are not historical facts, including statements concerning future securities registrations or other filings with the U.S. Securities and Exchange Commission ("SEC"), future treatment of patients with GBM using DCVax(R)-Brain, and other future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such a
|SOURCE Northwest Biotherapeutics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved